Hainan Poly Pharm Co Ltd - Asset Resilience Ratio
Hainan Poly Pharm Co Ltd (300630) has an Asset Resilience Ratio of 2.33% as of June 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read 300630 total debt and obligations for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2020–2022)
This chart shows how Hainan Poly Pharm Co Ltd's Asset Resilience Ratio has changed over time. See free cash flow generation of Hainan Poly Pharm Co Ltd to measure how efficiently the company converts operating cash flow to free cash.
Liquid Assets Composition Over Time
This chart breaks down Hainan Poly Pharm Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Hainan Poly Pharm Co Ltd assets under control.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥146.93 Million | 2.33% |
| Total Liquid Assets | CN¥146.93 Million | 2.33% |
Asset Resilience Insights
- Limited Liquidity: Hainan Poly Pharm Co Ltd maintains only 2.33% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Hainan Poly Pharm Co Ltd Industry Peers by Asset Resilience Ratio
Compare Hainan Poly Pharm Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Curaleaf Holdings Inc.
TO:CURA |
Drug Manufacturers - Specialty & Generic | 3.73% |
|
Yipinhong Pharmaceutical Co Ltd Class A
SHE:300723 |
Drug Manufacturers - Specialty & Generic | 1.01% |
|
Cronos Group Inc
TO:CRON |
Drug Manufacturers - Specialty & Generic | 69.94% |
|
Changzhou Qianhong Biopharma Co Ltd
SHE:002550 |
Drug Manufacturers - Specialty & Generic | 18.70% |
|
Hunan Warrant Pharmaceutical Co. Ltd. A
SHG:688799 |
Drug Manufacturers - Specialty & Generic | 0.40% |
|
Hunan Er Kang Pharmaceutical
SHE:300267 |
Drug Manufacturers - Specialty & Generic | 1.19% |
|
Sunflower Pharmaceuticals Group Co Ltd
SHE:002737 |
Drug Manufacturers - Specialty & Generic | 22.45% |
|
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
SHG:688505 |
Drug Manufacturers - Specialty & Generic | 11.06% |
Annual Asset Resilience Ratio for Hainan Poly Pharm Co Ltd (2020–2022)
The table below shows the annual Asset Resilience Ratio data for Hainan Poly Pharm Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2022-12-31 | 0.01% | CN¥455.91K ≈ $66.71K |
CN¥5.96 Billion ≈ $871.99 Million |
-1.51pp |
| 2021-12-31 | 1.51% | CN¥70.55 Million ≈ $10.32 Million |
CN¥4.66 Billion ≈ $682.23 Million |
+1.50pp |
| 2020-12-31 | 0.02% | CN¥550.35K ≈ $80.53K |
CN¥3.06 Billion ≈ $447.19 Million |
-- |
About Hainan Poly Pharm Co Ltd
Hainan Poly Pharm. Co., Ltd. engages in research, development, production, and sale of pharmaceutical drugs in China and internationally. The company's dosage formulations comprise of tablets, capsules, granules, ointments, eye drops, pre-infusion, injection, lyophilization, and oral solutions. It also offers pharmaceutical preparations, active pharmaceutical ingredients, other raw materials, exc… Read more